BriaCell Therapeutics Corp. just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on BriaCell Therapeutics Corp., plus every contract, funding round, and exec hire that follows, each with verified, ICP-ranked contacts.
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Get the full Deep Dive on BriaCell Therapeutics Corp. — free.
We'll email your report. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Contract Type
contract
VancouverBiotechnologyHealthcareHealth CareTherapeuticsDescription
BriaCell Therapeutics Corp. has announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant, with expected gross proceeds of approximately $5.55 million. The offering is expected to close on December 13, 2024.